Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.52 |
| ▸ | GPR4 | P46093 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 6/20 | 0.48 |
| ▸ | DRD2 | P14416 | 3/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.45 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14453658 | 0.87 | DRD3 (0.54) | EPHX2GPR4DRD3DRD2GPR119 | |
| SCHEMBL214604 | 0.86 | KDM4E (0.50) | EPHX2GPR4DRD3KDM4EALDH1A1 | |
| SCHEMBL13320335 | 0.85 | EPHX2 (0.52) | EPHX2 | |
| SCHEMBL13724597 | 0.85 | EPHX2 (0.58) | EPHX2GPR4DRD3DRD2GPR119 | |
| SCHEMBL215303 | 0.84 | EPHX2 (0.52) | EPHX2DRD2KDM4EALDH1A1 | |
| SCHEMBL14453585 | 0.83 | KCNA5 (0.62) | EPHX2GPR4DRD3DRD2 | |
| SCHEMBL19479118 | 0.83 | DRD3 (0.70) | DRD3DRD2ALDH1A1 | |
| SCHEMBL20423457 | 0.83 | DRD3 (0.55) | EPHX2GPR4DRD3DRD2GPR119 | |
| SCHEMBL1284266 | 0.83 | TLR8 (0.51) | EPHX2GPR4ACKR3 | |
| SCHEMBL214957 | 0.83 | EPHX2 (0.50) | EPHX2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| EP-2061768-A2 | IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | Exelixis, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008042282-A2 | IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | EXELIXIS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | EPHX2 2115/4885GPR4 3945/4885DRD3 4551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.